Doxazosin
- Generic Name
- Doxazosin
- Brand Names
- Cardura
- Drug Type
- Small Molecule
- Chemical Formula
- C23H25N5O5
- CAS Number
- 74191-85-8
- Unique Ingredient Identifier
- NW1291F1W8
- Background
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.
- Indication
Doxazosin is indicated to treat the symptoms of benign prostatic hypertrophy, which may include urinary frequency, urgency, and nocturia, among other symptoms. In addition, doxazosin is indicated alone or in combination with various antihypertensive agents for the management of hypertension. Off-label uses of doxazosin include the treatment of pediatric hypertension and the treatment of ureteric calculi.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Hypertension, Ureteric calculus
Japan Morning Surge-1 Study
- Conditions
- Hypertension
- First Posted Date
- 2006-02-02
- Last Posted Date
- 2006-02-02
- Lead Sponsor
- Japan Heart Foundation
- Target Recruit Count
- 600
- Registration Number
- NCT00285519
- Locations
- 🇯🇵
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan
Extracellular Fluid in Resistant Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2015-06-09
- Lead Sponsor
- St George's, University of London
- Target Recruit Count
- 32
- Registration Number
- NCT00141596
- Locations
- 🇬🇧
Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL, London, United Kingdom
Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension
- Conditions
- High Blood Pressure
- Interventions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT00130156
- Locations
- 🇨🇳
National Taiwan University Hospital., Taipei, Taiwan
Medical Therapy of Prostatic Symptoms
- Conditions
- Prostatic HyperplasiaProstatic Hypertrophy, Benign
- Interventions
- First Posted Date
- 2001-08-06
- Last Posted Date
- 2018-09-28
- Target Recruit Count
- 3407
- Registration Number
- NCT00021814
- Locations
- 🇺🇸
University of California, La Jolla, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸New York University School of Medicine, New York, New York, United States
Genetics of Hypertension Associated Treatments (GenHAT)
- Conditions
- HypertensionHeart DiseasesCoronary DiseaseMyocardial InfarctionCardiovascular Diseases
- Interventions
- First Posted Date
- 2000-09-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Donna Arnett, 257-5678
- Target Recruit Count
- 37939
- Registration Number
- NCT00006294
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Treatment of Mild Hypertension Study (TOMHS)
- Conditions
- Cardiovascular DiseasesHeart DiseasesHypertensionVascular Diseases
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT00000522
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
- Conditions
- Myocardial InfarctionCoronary DiseaseMyocardial IschemiaHeart FailureHypercholesterolemiaDiabetes MellitusHypertensionCardiovascular DiseasesHeart Diseases
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.